Drug Trial Radar · NCT05042362
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
Aug 27, 2021
Primary completion
Jul 25, 2023
Study completion Nov 27, 2023
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks. During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks. During the study, the participants will: * record information about the participants' hot flashes in an electronic diary * answer questions about the participants' symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.
Conditions
- Vasomotor Symptoms Associated With Menopause
- Hot Flashes
Interventions
Elinzanetant (BAY3427080)Drug
120 mg elinzanetant orally once daily
PlaceboDrug
Matching placebo orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).Time frame: From baseline to Week 4
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).Time frame: From baseline to Week 12
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).Time frame: From baseline to Week 4
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).Time frame: From baseline to Week 12
Locations
99 sites in 8 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics | Birmingham, AL
Birmingham, Alabama
Central Research Associates | Birmingham, AL
Birmingham, Alabama
Mesa Obstetricians and Gynecologists | Research Department
Mesa, Arizona
MomDoc Women's Health Research | Scottsdale, AZ
Scottsdale, Arizona
Noble Clinical Research | Tucson, AZ
Tucson, Arizona
Del Sol Research | Women Health studies
Tucson, Arizona
Applied Research Center of Arkansas
Little Rock, Arkansas
Alliance Research Institute | Bell Gardens, CA
Bell Gardens, California
Diagnamics | Encinitas, CA
Encinitas, California
Om Research LLC | Lancaster, CA
Lancaster, California
Northern California Research | Sacramento
Sacramento, California
IntimMedicine | Washington, DC
Washington D.C., District of Columbia
AMR - Fort Myers, FL
Fort Myers, Florida
Suncoast Clinical Research Inc | Pinellas
Palm Harbor, Florida
Physician Care Clinical Research LLC | Sarasota, FL
Sarasota, Florida
Medisense Inc. | Atlanta, GA
Atlanta, Georgia
Paramount Research Solutions | College Park Location
College Park, Georgia
Soapstone Center for Clinical Research, Inc. | Decatur, GA
Decatur, Georgia
Drug Studies America
Marietta, Georgia
M3 Wake Research Atlanta
Sandy Springs, Georgia
Clinical Research Prime
Idaho Falls, Idaho
Investigators Research Group, LLC
Brownsburg, Indiana
The Iowa Clinic - Ankeny
Ankeny, Iowa
Southern Clinical Research Associates | Metairie, LA
Metairie, Louisiana
Continental Clinical Solutions | Towson, MD
Towson, Maryland
Revive Research Institute, Inc. - Women's Health
Dearborn Heights, Michigan
Valley OBGYN
Saginaw, Michigan
Women's Clinic of Lincoln, P.C. | Lincoln, NE
Lincoln, Nebraska
Jubilee Clinical Research Inc | Las Vegas, NV
Las Vegas, Nevada
Affiliated Clinical Research, Inc. | Las Vegas, NV
Las Vegas, Nevada
M3 Wake Research - Clinical Research Center of Nevada
Las Vegas, Nevada
The Center for Womens Health & Wellness, LLC | Lawrenceville, NJ
Lawrenceville, New Jersey
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Velocity Clinical Research - Albuquerque
Albuquerque, New Mexico
Bosque Women's Care | Albuquerque, NM
Albuquerque, New Mexico
Circuit Clinical | OB GYN Associates of WNY
West Seneca, New York
OnSite Clinical Solutions - Charlotte
Charlotte, North Carolina
M3 Wake Research | Raleigh, NC
Raleigh, North Carolina
Unified Women's Clinical Research | Lyndhurst Clinical Research, Winston-Salem, NC
Winston-Salem, North Carolina
Axia Women's Health - Anderson Township
Cincinnati, Ohio
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.